Lead Product(s): Atrasentan Hydrochloride
Therapeutic Area: Nephrology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Chinook Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2020
Chinook Therapeutics in-license of atrasentan provides a unique opportunity for Chinook to add a potential new drug to its precision medicine portfolio for the treatment of rare CKD conditions.